AbbVie reports long-term vitiligo data for RINVOQ at EADV
AbbVie (NYSE:ABBV) presented Phase 3 study data at the 2026 EADV Congress, showing improved repigmentation in vitiligo patients treated with RINVOQ through 76 weeks. The data indicated increased facial and total body repigmentation. Combining RINVOQ with phototherapy showed higher response rates. RINVOQ is approved in the EU for vitiligo and is under FDA review in the U.S.
How this was made
The 30-second read
Why it matters
The data show a clear efficacy signal with no new safety issues, potentially expanding AbbVie's market and supporting its pipeline valuation.
Market read
Positive trial data may drive short‑term ABBV price appreciation and influence investor sentiment toward JAK inhibitor developers.
What to watch
Long-term safety profile and reimbursement considerations for a chronic skin condition may temper enthusiasm.
Background
AbbVie (NYSE:ABBV) disclosed Phase 3 trial results for RINVOQ in non‑segmental vitiligo at the 2026 EADV Congress.
Ticker impact
AbbVie presented new Phase 3 vitiligo data for RINVOQ showing improved repigmentation rates.
likely upward pressure as investors price in the favorable trial outcomes.
The data are the first detailed efficacy readout for vitiligo, a new indication for upadacitinib, and no safety concerns were reported.
Market effects
Strengthens the dermatology/autoimmune therapeutic segment and may lift peers developing JAK inhibitors.
European markets may react positively as the data were presented at a European conference.
Adds to the broader narrative of expanding uses for JAK inhibitors worldwide.
Counterpoint
If regulatory review stalls in the U.S., the upside could be limited despite strong data.
Key entities
- CompanyAbbVie
Pharmaceutical company presenting the trial data.
- DrugRINVOQ
Upadacitinib formulation being evaluated for vitiligo.
